Differential impact on post‐transplant outcomes between pulsatile‐ and continuous‐flow left ventricular assist devices

Abstract

Compared to XVE, patients with HMII have similar one- and three-yr survival after heart transplantation with less risk of early graft rejection and significant infection. With a strong shift toward use of continuous-flow LVADs, PTx outcomes are expected to continue to improve.